EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE )

Worel Nina iD, Schreder Martin iD, Tanzmann Andreas, Kurz Martin iD, Huber-Kraßnitzer Bianca, Neumeister Peter, Rosskopf Konrad, Sareban Nazanin, Branka Manuela, Kolovratova Vera, Oesterreicher Sophia, Koerbler Beatrix and 6 more

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70188 ↗

At a glance

Randomisierte kontrollierte Studie in Journal of Clinical Apheresis, 2026. Written by Worel Nina and 17 co-authors. Institution: Department of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria. Major MEDLINE topics: Multiple Myeloma, Cyclams, Benzylamines, Hematopoietic Stem Cell Mobilization. 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Sanofi Genzyme.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Efficient collection of hematopoietic progenitor cells (HPCs) is essential for autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Although plerixafor is routinely used in poor mobilizers, its role in patients with intermediate mobilization capacity remains unclear. In this randomized, double‐blind, placebo‐controlled phase IV trial, MM patients with peripheral blood (PB) CD34 + counts of 15–40 cells/μL after steady‐state G‐CSF mobilization were randomized to receive plerixafor or placebo. The primary endpoint was successful collection of ≥ 6.0 × 10 6 CD34 + cells/kg, sufficient for two ASCTs, during a single apheresis session. Secondary endpoints included CD34 + kinetics, graft composition, colony‐forming capacity, engraftment, immune reconstitution, and safety. Twenty‐one patients were enrolled before premature study termination due to changes in first‐line MM therapy and the COVID‐19 pandemic. Plerixafor significantly increased PB CD34 + cell counts compared with placebo ( p < 0.001). All patients receiving plerixafor achieved the primary endpoint, whereas none in the placebo group achieved it ( p < 0.001). Mean CD34 + yield was significantly higher with plerixafor (10.4 ± 1.9 × 10 6 /kg vs. 2.9 ± 1.3 × 10 6 /kg; p < 0.001). Plerixafor‐mobilized grafts contained significantly higher numbers of primitive hematopoietic progenitor subsets and demonstrated increased CFU‐GM formation, indicating enhanced clonogenic potential. Despite marked differences in graft quantity and quality, engraftment kinetics, graft sustainability, and immune reconstitution were comparable between groups. In MM patients with intermediate mobilization capacity, the addition of plerixafor markedly improved stem cell mobilization efficiency and enriched grafts with functionally robust progenitor cells. These findings suggest that selected patients beyond conventional poor mobilizers may benefit from plerixafor‐assisted mobilization. Trial Registration: EudraCT nr.: 2016‐004122‐41

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaCyclamsBenzylaminesHematopoietic Stem Cell MobilizationGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedAntigens, CD34Hematopoietic Stem Cell TransplantationTransplantation, AutologousAdultHematopoietic Stem Cells

Author keywords

autologous stem cell transplantationcolony‐forming unitshematopoietic stem cell mobilizationmultiple myelomaplerixaforstem cell graft composition

Substances

plerixaforCyclamsBenzylaminesGranulocyte Colony-Stimulating FactorAntigens, CD34Heterocyclic Compounds

Authors and institutions

  • Department of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
  • Department of Internal Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria.
  • Division of Hematology, Medical University of Graz, Graz, Austria.
  • Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
  • Department of Internal Medicine II, Clinic Donaustadt, Vienna, Austria.
  • Department of Internal Medicine 1, BMT-Unit, Medical University of Vienna, Vienna, Austria.

ORCID profiles: Worel Nina, Schreder Martin, Kurz Martin, Agis Hermine

Funding

  • Sanofi Genzyme

Cite

APA

Nina, W., Martin, S., Andreas, T., Martin, K., Bianca, H. K., Peter, N., Konrad, R., Nazanin, S., Manuela, B., Vera, K., Sophia, O., Beatrix, K., Elvira, K., Reinhard, R., Werner, R., Hermine, A., Maria, K., & T, G. H. (2026). Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE ). Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70188

Vancouver

Nina W, Martin S, Andreas T, Martin K, Bianca HK, Peter N, et al. Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE ). Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70188

BibTeX
@article{Nina2026,
  author = {Nina, Worel and Martin, Schreder and Andreas, Tanzmann and Martin, Kurz and Bianca, Huber-Kraßnitzer and Peter, Neumeister and Konrad, Rosskopf and Nazanin, Sareban and Manuela, Branka and Vera, Kolovratova and Sophia, Oesterreicher and Beatrix, Koerbler and Elvira, Kitzweger and Reinhard, Ruckser and Werner, Rabitsch and Hermine, Agis and Maria, Krauth and T, Greinix Hildegard},
  title = {Plerixafor and G‐ CSF Versus Placebo and G‐ CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results ( OPTIMIZE )},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70188}
}
Start for free →